0GO Stock Overview
A specialist pharmaceutical company, develops silica nanoparticle delivery systems to enhance the cellular delivery of cancer treatments, gene therapy, and vaccines in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
N4 Pharma Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.001 |
| 52 Week High | UK£0.026 |
| 52 Week Low | UK£0.001 |
| Beta | -0.40 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -85.71% |
| 3 Year Change | -97.73% |
| 5 Year Change | n/a |
| Change since IPO | -99.04% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0GO | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -2.2% | -2.0% |
| 1Y | -85.7% | -15.8% | 6.8% |
Return vs Industry: 0GO underperformed the German Pharmaceuticals industry which returned -15.6% over the past year.
Return vs Market: 0GO underperformed the German Market which returned 6.9% over the past year.
Price Volatility
| 0GO volatility | |
|---|---|
| 0GO Average Weekly Movement | 0% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine 0GO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 5 | Nigel Theobald | www.n4pharma.com |
N4 Pharma Plc, a specialist pharmaceutical company, develops silica nanoparticle delivery systems to enhance the cellular delivery of cancer treatments, gene therapy, and vaccines in the United Kingdom. It develops Nuvec, which offers silica nanoparticles with irregular surface structure and polyethyleneimine that traps and protects nucleic acid; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene for the treatment of glaucoma. The company was incorporated in 1979 and is based in London, the United Kingdom.
N4 Pharma Plc Fundamentals Summary
| 0GO fundamental statistics | |
|---|---|
| Market cap | €2.50m |
| Earnings (TTM) | -€1.30m |
| Revenue (TTM) | €7.06k |
353.7x
P/S Ratio-1.9x
P/E RatioIs 0GO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0GO income statement (TTM) | |
|---|---|
| Revenue | UK£5.86k |
| Cost of Revenue | UK£89.18k |
| Gross Profit | -UK£83.32k |
| Other Expenses | UK£994.73k |
| Earnings | -UK£1.08m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0027 |
| Gross Margin | -1,422.02% |
| Net Profit Margin | -18,399.86% |
| Debt/Equity Ratio | 0% |
How did 0GO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 08:58 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
N4 Pharma Plc is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Emma Ulker | Allenby Capital Limited |